Effect of the coronavirus disease 2019 pandemic on morbidity among children hospitalized for an asthma exacerbation

Alabdulkarim, Nada; Gai, Jiaxiang; Bost, James E.; Pillai, Dinesh K.; Teach, Stephen J.; Rastogi, Deepa

doi:10.1016/j.anai.2022.03.033

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…S e v e r a l p u b l i s h e d s t u d i e s f o u n d a n improvement in the rate of asthma control during the pandemic. [11][12][13][14] The Pediatric Asthma in Real Life (PeARL) survey and the World Allergy Organization (WAO) reported that 20% of patients had better asthma control, while 10% were negatively affected. 3 These findings are different from our results.…”

Section: Discussionmentioning

confidence: 99%

“…These differences may be related to the study population, since only patients with severe asthma were included. 3,[11][12][13][14] I n o u r s t u d y , t e l e m e d i c i n e c o u l d b e implemented quickly and effectively, without affecting asthma control, with a very good response from patients and their families. The strategy of providing remote care and returning to in-person consultations as loss of asthma control was detected was an effective tool for the followup of patients with severe asthma.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Follow-up of children diagnosed with severe asthma before and during the COVID-19 pandemic

2024

Arch Argent Pediat

View full text Add to dashboard Cite

During the COVID-19 pandemic, health care strategies were explored to ensure the follow-up of children with severe asthma. This was a prospective, observational, and comparative study. Patients in the severe asthma program of a tertiary care children's hospital were included (n: 74). The extent of control, exacerbations, and hospitalizations during an in-person period (IPP) (March 2019-2020) and an online period (OP) (April 2020-2021) was assessed.A total of 74 patients were enrolled in the IPP compared to 68 (92%) in the OP. During the IPP, 68% (46) of patients had exacerbations versus 46% (31) during the OP (p = 0.003). During the IPP, 135 total exacerbations were recorded compared to 79 during the OP (p = 0.001); this accounted for a 41% reduction. During the IPP, 47% (32) of patients had severe exacerbations versus 32% ( 22) during the OP (p = 0.048). A total of 91 severe exacerbations were recorded during the IPP compared to 49 during the OP (p = 0.029); the reduction was 46%. No differences were observed in terms of hospitalization (IPP: 10, OP: 6; p = 0,9). Telemedicine was effective for the follow-up of patients with severe asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Follow-up of children diagnosed with severe asthma before and during the COVID-19 pandemic

2024

Arch Argent Pediat

View full text Add to dashboard Cite

show abstract

“…The COVID-19 pandemic has affected the patterns of visits to medical institutions during asthma exacerbations. Patients with more severe asthma visited emergency departments and were hospitalized more often during versus before the pandemic [ 3 ]. To better predict the clinical outcomes of patients with asthma who become infected with SARS-CoV-2, several factors including the medical history, severity, and treatment of individual asthma cases should be considered.…”

Section: Asthmamentioning

confidence: 99%

Management of patients with allergic diseases in the era of COVID-19

Lee¹

2022

Clin Exp Pediatr

View full text Add to dashboard Cite

In the early days of the coronavirus disease 2019 (COVID-19) pandemic, allergic diseases, especially asthma, were considered to be risk factors for severe COVID-19 infection, hospitalization, and death. These concerns stemmed from the idea that individuals with allergic diseases are generally more susceptible to respiratory virus infections, which are major causes of exacerbation of allergic diseases.However, epidemiologic data with mechanistic studies showed that the associations between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes of allergic diseases are complex and affected by diverse factors such as allergic disease severity, phenotypes, and control status with current medications. In addition, children generally have less severe clinical outcomes of COVID-19 than those of adults, which complicates the association between allergic diseases and COVID-19-related outcomes among them. The present review summarizes the potential association between allergic diseases and COVID-19-related outcomes and discusses the factors requiring consideration. The findings viewed herein will aid the management of allergic diseases in patients with SARS-CoV-2 infection and the establishment of medical polices for managing patients with allergic diseases.

show abstract

“…Airway remodeling is an essential feature of asthma, manifested by structural changes in the airways, such as basement membrane thickening, bronchial fibrosis, airway smooth muscle cell hyperplasia, and hypertrophy ( 6 – 8 ). Among COVID-19 patients, uncontrolled asthma was identified as contributing factor to mortality, and patients also had more severe asthma manifestations during the pandemic ( 9 , 10 ). Therefore, considering the current COVID-19 epidemic and the high prevalence of asthma, the study results are timely.…”

Section: Introductionmentioning

confidence: 99%

Effect of SARS-CoV-2 infection on asthma patients

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundSARS-CoV-2 causes coronavirus disease 2019 (COVID-19), a new coronavirus pneumonia, and containing such an international pandemic catastrophe remains exceedingly difficult. Asthma is a severe chronic inflammatory airway disease that is becoming more common around the world. However, the link between asthma and COVID-19 remains unknown. Through bioinformatics analysis, this study attempted to understand the molecular pathways and discover potential medicines for treating COVID-19 and asthma.MethodsTo investigate the relationship between SARS-CoV-2 and asthma patients, a transcriptome analysis was used to discover shared pathways and molecular signatures in asthma and COVID-19. Here, two RNA-seq data (GSE147507 and GSE74986) from the Gene Expression Omnibus were used to detect differentially expressed genes (DEGs) in asthma and COVID-19 patients to find the shared pathways and the potential drug candidates.ResultsThere were 66 DEGs in all that were classified as common DEGs. Using a protein-protein interaction (PPI) network created using various bioinformatics techniques, five hub genes were found. We found that asthma has some shared links with the progression of COVID-19. Additionally, protein-drug interactions with common DEGs were also identified in the datasets.ConclusionWe investigated possible links between COVID-19 and asthma using bioinformatics databases, which might be useful in treating COVID-19 patients. More studies on populations affected by these diseases are needed to elucidate the molecular mechanism behind their association.

show abstract

Effect of the coronavirus disease 2019 pandemic on morbidity among children hospitalized for an asthma exacerbation

Cited by 7 publications

References 25 publications

Follow-up of children diagnosed with severe asthma before and during the COVID-19 pandemic

Follow-up of children diagnosed with severe asthma before and during the COVID-19 pandemic

Management of patients with allergic diseases in the era of COVID-19

Effect of SARS-CoV-2 infection on asthma patients

Contact Info

Product

Resources

About